Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Substitution: 'Devil' Is In Barriers To Switch In State Laws

Executive Summary

Brand and generic industries continue lobbying over provisions on ease of substitution; Utah is first state to remove sunset on pharmacist communication with physician. Interactive map and timeline detail key provisions and status of legislation in each state.


Related Content

Biosimilar Substitution: US State Laws Require Physician Communication And, In Some Cases, Lower Prices
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts